2023-26044. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA, we, or the Agency) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
DATES:
Submit written comments (including recommendations) on the collection of information by December 27, 2023.
ADDRESSES:
To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910–0119. Also include the FDA docket number found in brackets in the heading of this document.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–5733, PRAStaff@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
Good Laboratory Practice Requirements for Nonclinical Laboratory Studies—21 CFR Part 58
OMB Control Number 0910–0119—Extension
Sections 409, 505, 512, and 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 348, 355, 360b, and 360e) and related statutes require manufacturers of food additives, human drugs and biological products, animal drugs, and medical devices to demonstrate the safety and utility of their product by submitting applications to FDA for research or marketing permits. Such applications contain, among other important items, full reports of all studies done to demonstrate product safety in man and/or other animals. In order to ensure adequate quality control for these studies and to provide an adequate degree of consumer protection, the Agency issued good laboratory practice (GLP) regulations for nonclinical laboratory studies in part 58 (21 CFR part 58). The regulations specify minimum standards for the proper conduct of safety testing and contain sections on facilities, personnel, equipment, standard operating procedures (SOPs), test and control articles, quality assurance, protocol and conduct of a safety study, records and reports, and laboratory disqualification, and include information collection provisions.
Part 58 requires testing facilities engaged in conducting toxicological studies to retain, and make available to regulatory officials, records regarding compliance with GLPs. Records are maintained on file at each testing facility and examined there periodically by FDA inspectors. The GLP regulations require that, for each nonclinical laboratory study, a final report be prepared that documents the results of quality assurance unit inspections, test and control article characterization, testing of mixtures of test and control articles with carriers, and an overall interpretation of nonclinical laboratory studies. The GLP regulations also require written records pertaining to: (1) personnel job descriptions and summaries of training and experience; (2) master schedules, protocols and amendments thereto, inspection reports, and SOPs; (3) equipment inspection, maintenance, calibration, and testing records; (4) documentation of feed and water analyses and animal treatments; (5) test article accountability records; and (6) study documentation and raw data.
Description of Respondents: Respondents to the collection of information are sponsors of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by FDA.
In the Federal Register of August 8, 2023 (88 FR 53492), we published a 60-day notice soliciting comment on the proposed collection of information. One comment was received underscoring the critical nature of language translations in information exchange between international communities but did not suggest any modifications to our burden estimates.
We estimate the burden of this collection of information as follows: Start Printed Page 82907
Table 1—Estimated Annual Reporting Burden 1
21 CFR section Number of respondents Number of responses per respondent Total annual responses Average burden per response Total hours § 58.35(b)(7); Quality assurance unit 300 60.25 18,075 1 18,075 § 58.185; Reporting of nonclinical laboratory study results 300 60.25 18,075 27.65 499,774 Total 517,849 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Table 2—Estimated Annual Recordkeeping Burden1
21 CFR section Number of recordkeepers Number of records per recordkeeper Total annual records Average burden per recordkeeping Total hours § 58.29(b); Personnel 300 20 6,000 .21 (13 minutes) 1,260 § 58.35(b)(1)–(6), and (c); Quality assurance unit 300 270.76 81,228 3.36 272,926 § 58.63(b) and (c); Maintenance and calibration of equipment 300 60 18,000 .09 (5 minutes) 1,620 § 58.81(a)–(c); SOPs 300 301.80 90,540 .14 (8 minutes) 12,676 § 58.90(c) and (g); Animal care 300 62.70 18,810 .13 (8 minutes) 2,445 § 58.105(a) and (b); Test and control article characterization 300 5 1,500 11.8 17,700 § 58.107(d); Test and control article handling 300 1 300 4.25 1,275 § 58.113(a); Mixtures of articles with carriers 300 15.33 4,599 6.8 31,273 § 58.120; Protocol 300 15.38 4,614 32.7 150,878 § 58.195; Retention of records 300 251.50 75,450 3.9 294,255 Total 786,308 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Based on an evaluation of the information collection, we are retaining the currently approved estimates. Our assumptions made regarding the time needed for the respective activities is based on our experience with the information collection and informal communications with respondents.
Start SignatureDated: November 21, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–26044 Filed 11–24–23; 8:45 am]
BILLING CODE 4164–01–P
Document Information
- Published:
- 11/27/2023
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2023-26044
- Dates:
- Submit written comments (including recommendations) on the collection of information by December 27, 2023.
- Pages:
- 82906-82907 (2 pages)
- Docket Numbers:
- Docket No. FDA-2023-N-2894
- PDF File:
- 2023-26044.pdf